Skip to main content
Premium Trial:

Request an Annual Quote

GSK Enters New Adverse-Event Pharmacogenomics Pact with FGT

This article has been updated to include comments from an FGT spokesman.

 

NEW YORK, May 25 (GenomeWeb News) - First Genetic Trust said today that it will apply its enTrust genetic banking platform in a research collaboration with GlaxoSmithKline to study the relationship between genetic variations and certain adverse drug reactions.

 

The companies entered a similar collaboration in October 2001. A company spokesman said that the current agreement marks an entirely new study, rather than an extension of the previous one. The initial study was focused more on developing the platform, he said, "and now we're using the platform to do another study."     

 

FGT was unable to provide further details on the new study.

 

FGT said that GSK will use enTrust to collect, store, and manage patient enrollment, informed consent, and clinical data to support the project.

 

The system will also be used to re-contact patients online for additional consent for new research or phenotypic information, FGT said.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.